Home
Independent European equity research
The research desk,without theresearch budget.
Concise, independent views on hundreds of European listed companies. Written by hedge fund managers and former sell-side analysts for investors who want an independent, informed read on European companies.
Still being written. Notes go up as companies report and news breaks.
- Mayr-MelnhofMMK
The new range leaves the mills it keeps near break-even at best
- UbisoftUBI
A hit remake lifted the quarter, but the year hangs on when partner deals land
- BASFBAS
Dropping Evonik keeps the payout promise safe, but extra payouts look unlikely
- SantanderSAN
Insmed would cost earnings first, because the premium pays for sales still years away
- SolariaSLR
The 2029 goal mostly adds a year to the old plan, and leans on batteries
Why Lux Opes
What the big houses sell, minus the overhead.
Large research houses bundle basic maintenance research and 50+ page reports full of fluff into one expensive package. We do our own work on the part professionals actually use: what changed at a company, what it means, and what would prove us wrong.
Pan-European, large to small.
575 companies across 21 countries so far, from index heavyweights to the small and mid caps that brokers have stopped covering.
The point, not the padding.
No 50-page reports. Each company gets what moved and what it means for the investment case, in a few lines you can read between meetings.
No ratings. No banking ties.
We don’t issue buy or sell calls and have no corporate finance business to protect. You bring the judgement; we bring the information.
The comparison
Traditional research vs Lux Opes.
Since MiFID II, research has had a price tag, and most of it is set for institutional budgets. Here is where we differ.
Inside an edition
What lands in your inbox.
A sample from 19 Nov 2026. One short take per company, each tagged with our read of the news.
The new range leaves the mills it keeps near break-even at best
Austria · MMKRead →A hit remake lifted the quarter, but the year hangs on when partner deals land
France · UBIRead →Dropping Evonik keeps the payout promise safe, but extra payouts look unlikely
Germany · BASRead →Insmed would cost earnings first, because the premium pays for sales still years away
Spain · SANRead →The 2029 goal mostly adds a year to the old plan, and leans on batteries
Spain · SLRRead →Berlin's deal leaves the bank's other holders without an ally on price
Germany · CBKRead →The coverage
Every company, every edition, one place.
Search all 575 companies we’ve written about, see how the takes have moved over time, and jump straight to each edition.
Open the coverage trackerTemperament matters as much as fundamentals. On the fundamentals, we can help.Lux Opes Research
- 01No long reportsConcise by design, so you can cover more ground.
- 02No multi-bagger promisesJust material information, clearly framed.
- 03No buy or sell callsThe decision stays yours, but we always share our view.
- 04The full archiveEvery edition and every company since January 2025.
Join 40,000+ investors
Cover more of Europe, for less.
The European companies that matter, framed by people who have worked on both the buy side and the sell side.
Lux Opes Research provides information and commentary only. Nothing here is investment advice or a recommendation to buy or sell any security.